INHAL 101
Alternative Names: INHAL-101Latest Information Update: 04 Sep 2023
At a glance
- Originator Inhalis Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4 protein inhibitors; MTOR protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 23 Aug 2023 Pharmacodynamic, pharmacokinetic and adverse events data from a preclinical study in Idiopathic pulmonary fibrosis released by Inhalis Theraputics (Inhalis Therapeutics pipeline, August 2023)
- 21 Aug 2023 Inhalis Therapeutics files for a patent application of INHAL 101
- 21 Aug 2023 Preclinical trials in Idiopathic pulmonary fibrosis in Switzerland (Inhalation), prior to August 2023